Neuroleptic malignant syndrome associated with abrupt withdrawal of anticholinergic agents

International Clinical Psychopharmacology

Volumn 11, Issue 3, 1996, Pages 207-209

  Spivak, B ^a,c   Gonen, N ^a,c   Mester, R ^a,c   Averbuch, E ^a   Adlersberg, S ^a   Weizman, A ^b,c  

^a NESS ZIONA MENTAL HEALTH CENTER   (Israel)

^b GEHA MENTAL HEALTH CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Anticholinergic agents; Neuroleptic discontinuation; Neuroleptic malignant syndrome (NMS)

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLUPHENAZINE DECANOATE; PENFLURIDOL; TRIHEXYPHENIDYL;

ADULT; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NEUROLEPTIC MALIGNANT SYNDROME; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; FLUPHENAZINE; HUMANS; MALE; MUSCARINIC ANTAGONISTS; NEUROLEPTIC MALIGNANT SYNDROME; PENFLURIDOL; PROCYCLIDINE; SCHIZOPHRENIA; SUBSTANCE WITHDRAWAL SYNDROME; TRIHEXYPHENIDYL;

EID: 0029825771     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199609000-00009     Document Type: Article

References (11)

1. Abbot RJ and Loizon LA (1986) Neuroleptic malignant syndrome. British Journal of Psychiatry, 148, 47-51.
2. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders. 4th edn (DSM-IV). APA, Washington, DC.
3. Calne DB (1977) Developments in the pharmacology and therapeutics of Parkinsonism. Annals of Neurology, 1, 111-119.
4. Cape G (1994) Neuroleptic malignant syndrome - a cautionary tale, a surprising outcome. British Journal of Psychiatry, 164, 120-122.
5. Caroff SN (1980) The neuroleptic malignant syndrome. Journal of Clinical Psychiatry, 41, 79-83.
6. Fricchione GL (1985) Neuroleptic catatonia and its relationship to psychogenic catatonia. Biological Psychiatry, 20, 304-313.
7. Gurrera RJ, Chang SS and Romero JA (1992) A comparison of diagnostic criteria for neuroleptic malignant syndrome. Journal of Clinical Psychiatry, 53, 56-62.
8. Sakkas P, Davis JM, Janicak PG and Wang Z (1991) Drug treatment of the neuroleptic malignant syndrome. Psychopharmacology Bulletin, 27, 381-384.
9. Shalev A and Munitz H (1986) The neuroleptic malignant syndrome: agent and host interaction. Ada Psychiatrica Scandinavica, 73, 337-347.
10. Spivak B, Weizman A, Wolovick L, Hermesh H, Tyano S and Munitz H (1990) Neuroleptic malignant syndrome during abrupt reduction of neuroleptic treatment. Acta Psychiatrica Scandinavica, 81, 168-169.
11. Sternberg DE (1986) Neuroleptic malignant syndrome: the pendulum swings. American Journal of Psychiatry, 143, 1273-1275.